LU 177 coming soon to the US

[HopingForTheBest1]

There is now a name for LU177 treatment here in the US. It is called LUTATHERA, and is made by an affiliate of Novartis. Their patient website is lutathera.com . They have been ramping up production in advance of the coming FDA approval expected in the next 3 months.

[tango65]

Lutathera is not a Lu 177 PSMA ligand for PC treatment. It is a treatment targeting neuro endocrine tumors.

novartis.us/sites/www.novar...

hcp.lutathera.com/about-lut...

[Tall_Allen]

No. Lutathera is NOT for prostate cancer. You were misled by the radioactive element (Lu-177) that they both contain. But the important part of the molecule is what it attaches to. For prostate cancer, Lu-177-PSMA-617 attaches to the PSMA protein on the surface of the prostate cancer cell. For neuroendocrine cancers that express somatostatin, Lu177-DOTATATE (Lutathera) attaches to the somatostatin protein on those cells,

[HopingForTheBest1 in reply to Tall_Allen]

Thank you for the clarification.

[slpdvmmd]

While Lutathera is not for Prostate Cancer its history is similar. Scan (Dotatate PET/CT) available for imaging of gastric neuroendocrine tumors followed by development of Lu177 radioligand therapy. Both scans and treatment available for a long time overseas before finally being approved in the USA. My medical oncologist told me that as a fellow at MD Anderson a couple decades ago they counseled people with neuroendocrine tumors on the availability of imaging and radioligand therapy overseas. So similar delays in availability here in the United States to PSMA for scans and Lu 177 linked radioligand therapy. Interestingly, Dotatate scans can also be used for imaging of meningiomas and have demonstrated "sister" lesions missed on standard scans. Also Lu177 dotate/Lutathera is being used for treatment of deep/in-operable brain meningiomas overseas and can result in lowering of the total brain radiation dosage when used in conjunction with external beam radiation. One of my radiation oncologists told me the USA is now trialing meningioma imaging with Dotatate PET/CT. She expects lag time to approval here in the US will be similar to delays for scans and radioligand therapies for neuroendocrine and prostate cancer.